| Bioactivity | AC-264613 is a potent and selective protease-activated receptor (PAR-2) agonist with a pEC50 of 7.5[1]. |
| Target | pEC50: 7.5 (PAR-2) |
| Invitro | AC-264613 (10 μM; for 6 hours) causes a decrease of IRF5 expression and also significantly reduces p53 protein expression in macrophages[2]. Western Blot Analysis[2] Cell Line: |
| In Vivo | AC-264613 exhibits moderate elimination half-live (T1/2=2.5±2.0 h) following i.p. administration (10 mg/kg) in male Sprague-Dawley rats[3]. |
| Name | AC-264613 |
| CAS | 1051487-82-1 |
| Formula | C19H18BrN3O2 |
| Molar Mass | 400.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jimmi Gerner Seitzberg, et al. Discovery of potent and selective small-molecule PAR-2 agonists. J Med Chem. 2008 Sep 25;51(18):5490-3. [2]. Rui Yamaguchi, et al. A protease-activated receptor 2 agonist (AC-264613) suppresses interferon regulatory factor 5 and decreases interleukin-12p40 production by lipopolysaccharide-stimulated macrophages: Role of p53. Cell Biol Int. 2016 Jun;40(6):629-41 [3]. Luis R Gardell, et al. Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. J Pharmacol Exp Ther. 2008 Dec;327(3):799-808. |